within Pharmacolibrary.Drugs.ATC.G;

model G04BE52
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.3,
    Cl             = 0.016666666666666666,
    adminDuration  = 600,
    adminMass      = 150 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.003,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0014166666666666668,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G04BE52</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Papaverine is an opium alkaloid antispasmodic drug, primarily used for its vasodilating effects on smooth muscle. It has been used historically for treatment of conditions such as vasospasm, erectile dysfunction and certain types of colic, but is less commonly used today due to the availability of more selective agents. The 'combinations' in ATC code G04BE52 generally indicate pairing papaverine with other agents for urological indications.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic studies or models specific to papaverine combinations (ATC G04BE52) in humans were identified as of 2024. Main available PK data are for papaverine alone in adults, typically healthy male volunteers.</p><h4>References</h4><ol><li><p>Porst, H, et al., &amp; Sharlip, I (2013). SOP conservative (medical and mechanical) treatment of erectile dysfunction. <i>The journal of sexual medicine</i> 10(1) 130–171. DOI:<a href=\"https://doi.org/10.1111/jsm.12023\">10.1111/jsm.12023</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23343170/\">https://pubmed.ncbi.nlm.nih.gov/23343170</a></p></li><li><p>Vargay, Z, et al., &amp; Eckhardt, S (1984). The fate of drotaverine-acephyllinate in rat and man. II. Human pharmacokinetics of drotaverine-14C-acephyllinate. <i>European journal of drug metabolism and pharmacokinetics</i> 9(1) 17–29. DOI:<a href=\"https://doi.org/10.1007/BF03189602\">10.1007/BF03189602</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/6546919/\">https://pubmed.ncbi.nlm.nih.gov/6546919</a></p></li><li><p>Mutha, AS, et al., &amp; Patel, SB (2015). An Observational Study to Evaluate the Prevalence of Erectile Dysfunction (ED) and Prescribing Pattern of Drugs in Patients with ED Visiting an Andrology Specialty Clinic, Mumbai: 2012-14. <i>Journal of clinical and diagnostic research : JCDR</i> 9(7) PC08–PC11. DOI:<a href=\"https://doi.org/10.7860/JCDR/2015/14520.6174\">10.7860/JCDR/2015/14520.6174</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26393163/\">https://pubmed.ncbi.nlm.nih.gov/26393163</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G04BE52;
